Detalles de la búsqueda
1.
Non-viral precision T cell receptor replacement for personalized cell therapy.
Nature
; 615(7953): 687-696, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36356599
2.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 379(22): 2108-2121, 2018 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30345906
3.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30297397
4.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(4): 375-e30, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28275117
5.
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Oncologist
; 22(10): 1281, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29018169
6.
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Clin Cancer Res
; 14(8): 2465-75, 2008 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18413839
7.
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
JAMA Oncol
; 5(3): 334-342, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30347025
8.
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Eur J Cancer
; 101: 114-122, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30053670
9.
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
J Thorac Oncol
; 13(11): 1733-1742, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29775807
10.
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Nat Commun
; 7: 12624, 2016 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-27571927
11.
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
J Thorac Oncol
; 7(1): 219-26, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22011666
12.
Molecular analysis of the acetolactate synthase gene of Chlamydomonas reinhardtii and development of a genetically engineered gene as a dominant selectable marker for genetic transformation.
Plant J
; 29(1): 109-17, 2002 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12060231
Resultados
1 -
12
de 12
1
Próxima >
>>